<DOC>
	<DOCNO>NCT00995540</DOCNO>
	<brief_summary>INGAP Peptide acetate active ingredient INGAP Peptide Solution Injection . It develop antidiabetic agent restoration endogenous insulin secretion patient type 1 diabetes mellitus ( T1DM ) insulin-deficient patient type 2 diabetes mellitus ( T2DM ) . This clinical study design generate additional data regard appropriate dose dose regimen evaluate safety efficacy patient T1DM .</brief_summary>
	<brief_title>Tolerability , Safety , Efficacy Study INGAP Peptide Treat Type 1 Diabetes Mellitus Adults</brief_title>
	<detailed_description>In contrast currently approve therapy direct control either metabolic abnormality tissue complication diabetes , INGAP Peptide therapy intend restore ß cell mass islet cell function . INGAP Peptide identify substance induces islet cell regeneration progenitor cell resident pancreas manner recapitulates islet development normal embryogenesis . INGAP Peptide therapy evaluate phase 1 2 study T1DM T2DM patient ( Dungan K , Diab Met Res Rev 2009 ; 25:558-565 ) . Once daily injection INGAP Peptide 3 month cause statistically significant increase C peptide secretion T1DM patient , trend towards increase C-peptide level see T2DM patient . Glycosylated hemoglobin ( HbA1c ) decrease -0.6 % ( p &lt; 0.0125 ) T2DM patient -0.4 % ( p &lt; 0.06 ) T1DM patient . Given short half-life INGAP Peptide ( i.e. , &lt; 1 hour ) , finding earlier phase 2 study patient T1DM T2DM encourage despite suboptimal exposure drug , evidence efficacy . Local injection site reaction observe study may due relatively large dos formulation optimized tonicity patient comfort . This study design dose INGAP Peptide divide across three daily administration use formulation improve respect tonicity . The study evaluate safety , tolerability C-peptide response associate dose regimen patient T1DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patients meet follow criterion eligible enrollment study : Male female patient age 19 60 year old , inclusive , history T1DM &gt; 2 year ≤40 year ; Receiving multiple daily insulin injection insulin pump therapy &gt; 2 year ; Body mass index ( BMI ) ≤32 kg/m2 ; HbA1c ≤7.7 % ; Fasting Cpeptide level &lt; 0.6 ng/mL Willing sign study inform consent document ; In good general health late severe complication concomitant medical condition would influence outcome trial , discretion Investigator Sponsor ; If treat angiotensinconverting enzymes/angiotensin II receptor blocker ( ACE/ARB ) , dos unchanged month prior enrollment ; Females child bear potential must negative urine pregnancy test Day 0 prior dispense drug additionally fulfill one follow criterion : Willing use oral , implantable , transdermal , injectable contraceptive 21 day prior first dose 28 day last dose ; , Willing use another reliable mean contraception approve Investigator ( intrauterine device , female condom , diaphragm spermicide , cervical cap , use condom sexual partner , sterile sexual partner ) Screening last blood sample ( Week 16 ) . Patients meet follow criterion exclude study participation : • Total daily insulin dosage exceed 1.0 U/kg/day change total daily insulin dose level 50 % ( increase decrease ) within past 3 month ; Treatment diabetes medication insulin ; A score 4 restricted response Clarke Hypoglycemia Awareness Survey ; Systolic diastolic blood pressure &gt; 180 mmHg &gt; 110 mmHg , respectively ; Clinical worsen retinopathy neuropathy previous 3 month ; Clinical worsen nephropathy previous 3 month , blood urea nitrogen ( BUN ) serum creatinine exceed 50 mg/dL 2.0 mg/dL , respectively ; History presence acute chronic pancreatitis , include serum amylase level &gt; 1.5 time upper limit normal ( ULN ) serum lipase level &gt; 2 time ULN ; A history presence illness , disease , condition could impact patient safety evaluability drug effect , Investigator 's opinion ; An episode severe hypoglycemia ( change mental status require assistance ) previous 30 day ; An episode acute glycemic decompensation associate hyperosmolar nonketotic state diabetic ketoacidosis past 6 month ; A serum aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin level &gt; 2 time ULN ; Received investigational product within 30 day admission study prior exist exposure INGAP Peptide glucagonlike peptide ( GLP 1 , GLP 2 , analog ) ; Concurrent plan participation clinical study conduct study ; Positive urine test cocaine , opiates , amphetamine , cannabinoids ; Inability fill maintain daily diary screening period prior dose ; , Human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C seropositivity blood sample take screening .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>T1DM</keyword>
	<keyword>Regeneration</keyword>
	<keyword>Islet</keyword>
	<keyword>Beta cell</keyword>
	<keyword>INGAP Peptide</keyword>
</DOC>